Excalipoint Therapeutics launched with an oversubscribed $68.7 million seed round to advance a portfolio of T-cell engagers for solid tumors. The financing positions the company among the larger early-stage raises in China biotech, with proceeds intended to drive early development toward later clinical proof. The company’s pipeline centers on T-cell engager modalities designed to engage and redirect immune responses against solid-tumor targets. Excalipoint’s seed round suggests investors are continuing to fund “engager-first” oncology strategies despite intense competition and shifting valuations. For the field, the round adds capital to a class of therapeutics that has shown differentiated potential in hematologic malignancies and remains under active optimization in solid tumors—particularly around safety, trafficking, and antigen expression. Excalipoint’s establishment also signals that Chinese biotech remains an active source of early clinical oncology innovation as investors seek scalable clinical programs.